Luye Pharma Group Completes Key Investment Phase

Luye Pharma Group (HK:2186) has released an update.

Luye Pharma Group Ltd. has successfully completed the initial phase of a significant investment deal with a third party in Shenzhen Luye, resulting in the Group retaining a 75% ownership and the Investor holding 25%. This strategic move, which includes an investor-nominated director joining Nanjing Luye’s board, signals the Group’s advancement to the next stage of investment, with future updates to be announced in due course.

For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.